Pfizer Inc. (NYSE:PFE) Plans $0.43 Quarterly Dividend

Key Points

• Pfizer Inc. has declared a quarterly dividend of $0.43 per share, which translates to an annualized yield of 6.8%, with payment set for December 1st to stockholders on record by November 7th.
• The company's earnings report for the last quarter showed an earnings per share (EPS) of $0.78, surpassing expectations and reflecting a 10.3% increase in revenue compared to the previous year.
• Equities analysts have set a consensus target price for Pfizer shares at $28.41, with the stock currently rated as "Hold" by most analysts, indicating a cautious outlook on its future performance.

Pfizer Inc. (NYSE:PFE - Get Free Report) declared a quarterly dividend on Thursday, October 9th, RTT News reports. Stockholders of record on Friday, November 7th will be given a dividend of 0.43 per share by the biopharmaceutical company on Monday, December 1st. This represents a c) dividend on an annualized basis and a dividend yield of 6.8%.

Pfizer has a payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Pfizer to earn $3.03 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 56.8%.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.46 during midday trading on Thursday, reaching $25.22. 47,130,201 shares of the company's stock were exchanged, compared to its average volume of 46,843,336. The company's 50 day simple moving average is $24.79 and its two-hundred day simple moving average is $24.15. The firm has a market capitalization of $143.39 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 0.86 and a beta of 0.55. Pfizer has a 12 month low of $20.92 and a 12 month high of $30.08. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. UBS Group reiterated a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Finally, Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.